The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 296.00
Bid: 295.00
Ask: 299.00
Change: -8.00 (-2.63%)
Spread: 4.00 (1.356%)
Open: 292.00
High: 298.00
Low: 292.00
Prev. Close: 304.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Omega Diagnostics Visitect not available in UK

Fri, 11th Mar 2022 11:15

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

DeepVerge PLC, up 6.9% at 15.50 pence, 12-month range 12.50p-36.25p. Production orders for its Modern Water division in the first quarter grew to GBP5 million and stated that it is transitioning its business model. Deepverge says orders received this quarter reflect year-on-year growth of 39% compared to orders worth GBP3.6 million a year before. These new orders for the Modern Water division also represent the biggest first-quarter production order in the history of the division. The equipment is expected to be delivered this year. The company stated that it will still deliver units as it transitions to monitoring. This includes units for a Chinese State government department and multiple units on its Yangtze River project, which are capital equipment sales.

----------

Mkango Resources Ltd, up 12% at 26.49 pence, 12-month range 19.00p-37.50p. Secures financing from European Raw Materials Alliance for the development of a rare earth separation plant in Poland. This plant will be supplied with rare earth carbonate from Mkango's Songwe Hill deposit of rare earth elements in Malawi. Mkango says the project will aid the creation of a secure supply chain option for neodymium, praseodymium, dysprosium, and terbium for the EU.

----------

AIM - LOSERS

----------

Hutchmed (China) Ltd, down 9.5% at USD26.30, 12-month range USD26.30-USD77.60. Sinks to 12-month low as its depositary shares may be delisted from New York's Nasdaq exchange in early 2024 unless the Holding Foreign Companies Accountable Act is amended to exclude Hutchmed. The act is part of regulatory focus in the US on access to audit and other information. It requires the US Securities & Exchange Commission to prohibit the securities of any company from being traded on any of the US securities exchanges if the auditor of the company's financial statements is not subject to inspection by the US Public Co Accounting Oversight Board for three consecutive years. Another way for Hutchmed to be excluded from the act is if the PCAOB is able to conduct a full inspection of the company's auditor during the required timeframe.

----------

Omega Diagnostics Group PLC, down 11% at 3.68 pence, 12-month range 3.68p-98.50p. Says its Visitect Covid-19 antigen test has not been approved by the UK Health Security Agency for professional use. As a result, the product will not be available for sale in the UK. The company continues to work with external study centres to ensure the deadline for submission of self-test CE Mark data is met on March 31. Omega says it believes the self-test market to be "more relevant in terms of opportunity".

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2023 13:47

Hutchmed China completes enrolment for solveplenib clinical trial

(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for 'ESLIM-01', a pivotal phase 3 clinical trial of sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (ITP) in China.

Read more
3 Jan 2023 10:28

Hutchmed completes patient enrolment for ITP clinical trial in China

(Alliance News) - Hutchmed (China) Ltd on Tuesday said it has completed patient enrolment for its clinical trial exploring potential treatment therapies for adults with primary immune thrombocytopenia in China.

Read more
19 Dec 2022 19:29

TRADING UPDATES: Tekcapital's MicroSalt plans IPO in 2023

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
15 Nov 2022 11:30

Hutchmed refocuses strategy away from early-stage studies

(Sharecast News) - Hutchmed China updated the market on its strategy on Tuesday, following an "in-depth evaluation" of the business.

Read more
15 Nov 2022 10:52

Hutchmed China to shift strategy toward advanced assets in pipeline

(Alliance News) - Hutchmed (China) Ltd announced on Tuesday it will shift focus towards its most advanced assets from its internal developed pipeline, following an evaluation of the business.

Read more
14 Nov 2022 16:55

LONDON MARKET CLOSE: Europe ends higher but New York struggles

(Alliance News) - European equities surrendered some afternoon gains but made a bright start to the week on Monday, shaking off hawkish noise from the US Federal Reserve, while investors waited with bated breath for the outcome of talks between the leaders of the world's two leading economies.

Read more
14 Nov 2022 14:20

IN BRIEF: Hutchmed sees positive results for gastric cancer drug

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. Explains the drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase-three study in 703 patients, which the firm says is "clinically meaningful". Fruquintinib also shows a "statistically significant improvement" in secondary endpoints including objective response rate, disease control rate, and improved duration of response, Hutchmed adds. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

Read more
14 Nov 2022 10:27

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
14 Nov 2022 09:40

Hutchmed reports positive results from recent fruquintinib study

(Sharecast News) - Hutchmed China announced initial results from the 'FRUTIGA' phase 3 study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma on Monday.

Read more
27 Oct 2022 14:27

IN BRIEF: Hutchmed begins phase II/III trial of fruquintinib

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins randomised, open-label, active-controlled phase II/III trial of fruquintinib combination with sintilimab in China. The trial will explore the combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma - the most common type of kidney cancer. The first patient in China received the dose on Thursday, it says.

Read more
10 Oct 2022 10:24

Hutchmed begins sovleplenib trial for anaemia treatment in China

(Alliance News) - Hutchmed China Ltd on Monday said it has begun a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune haemolytic anaemia in China.

Read more
8 Sep 2022 11:02

Hutchmed posts positive results for CRC cancer treatment

(Alliance News) - Hutchmed China Ltd on Thursday said that its fruquintinib treatment reduced risk of death by 34% in metastatic colorectal cancer patients.

Read more
9 Aug 2022 10:04

Hutchmed notes dosing of first participant in IMG-004 study

(Alliance News) - Hutchmed China Ltd on Tuesday said it has dosed its first participant in its global phase one trial of IMG-004.

Read more
8 Aug 2022 12:42

Hutchmed upbeat on latest study results for colorectal cancer treatment

(Sharecast News) - Hutchmed China announced on Monday that the "pivotal" global phase three trial evaluating the investigational use of 'fruquintinib' met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer (CRC).

Read more
8 Aug 2022 11:32

UPDATE: Hutchmed, AstraZeneca move lung cancer drug to phase 3 trial

(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objective response rate, and has moved the drug into phase 3 trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.